Free Trial
NASDAQ:GRCE

Grace Therapeutics Q3 2025 Earnings Report

Grace Therapeutics logo
$2.79 -0.11 (-3.79%)
As of 03:48 PM Eastern

Grace Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, February 12, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Grace Therapeutics' Q4 2025 earnings is scheduled for Friday, June 20, 2025, with a conference call scheduled on Monday, June 23, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Grace Therapeutics Earnings Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

View Grace Therapeutics Profile

More Earnings Resources from MarketBeat